Date：Oct 5, 2025
39 microcap IPOs priced in Q3, raising $414.8 million across the exchanges.
July: 18 IPOs – $202M raised, August: 16 IPOs – $167M raised, September: 5 IPOs – $44.9M raised.
35 listed on U.S. Nasdaq, 4 on NYSE.
8 domestic issuers, 31 foreign private issuers (FPIs). The U.S. public microcap market is currently primarily serving as a capital formation venue for international companies, not U.S. small businesses. The FPI dominance indicates investor interest in geographic diversification and specific growth stories from regions like Asia, Europe, and Israel.
Possible Drivers:
- Regulatory Arbitrage: FPIs benefit from lighter reporting requirements (e.g., 20-F vs 10-K, exemption from many proxy rules), making a U.S. listing less burdensome.
- Access to Deep Capital: Foreign companies seek the liquidity and prestige of U.S. exchanges.
Risk appetite improved as broader IPO indices outperformed the S&P 500 and the Russell Microcap Index rallied over 17%, helped by a Fed rate cut and easing trade tensions, which supported small-cap valuations and aftermarket performance
Microcap listings in 2025 have been heavily skewed to Nasdaq, which accounts for the vast majority of sub-$50M deals, while NYSE has remained a smaller but steady venue (around a tenth of US IPOs overall).
Cancellations and withdrawals dropped sharply versus prior quarters, indicating that issuers who made it onto the calendar generally got out, but the sizing and pricing of microcap deals point to continued investor leverage in negotiations.
The U.S. Government shutdown risk and regulatory overhang (SEC funding questions and exchange rule changes) created headline noise, yet the strong overall IPO statistics and microcap index performance suggest that for credible microcaps—especially FPIs with sector tailwinds—the Q3 window was attractive but required realistic valuation and tighter structures.
